Labetalol-Induced Hepatotoxicity during Pregnancy: A Case Report

Abstract Background Drug-induced liver injury is a common cause of transaminitis, occurring in up to 5% of patients who are hospitalized for liver failure. In pregnancy, transaminitis is seen in conditions which may require expedited delivery. Case A 39-year-old G2P0010 at 272/7 weeks' gestation with chronic hypertension on labetalol was found to have elevated transaminases. Evaluation for preeclampsia, acute fatty liver, nonalcoholic steatohepatitis, cholelithiasis, infections, and autoimmune conditions were all negative. Labetalol was then discontinued, and liver biopsy was performed. After discontinuation of labetalol, her hepatitis improved, and she was discharged on hospital day 12 and went on to deliver at term. Conclusion Labetalol-induced hepatitis should be considered in the differential for transaminitis during pregnancy to prevent iatrogenic preterm delivery.

[1]  ACOG Practice Bulletin No. 29: Chronic Hypertension in Pregnancy , 2001, Obstetrics and gynecology.

[2]  B. Mathieu,et al.  Fatal intoxication with labetalol (Trandate). , 2008, Forensic science international.

[3]  M. Wofford,et al.  Hepatocellular Necrosis Associated With Labetalol , 2007, Journal of clinical hypertension.

[4]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[5]  A. Stronkhorst,et al.  A case of labetalol-induced hepatitis. , 1992, Netherlands Journal of Medicine.

[6]  H. Zimmerman,et al.  Labetalol hepatotoxicity. , 1990, Annals of internal medicine.

[7]  P. Jensen,et al.  Fatal labetalol-induced hepatic injury. , 1989, The American journal of medicine.

[8]  J. McNeil,et al.  Clinical Pharmacokinetics of Labetalol , 1984, Clinical pharmacokinetics.